A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open‐label proof‐of‐concept study
- 21 June 2011
- journal article
- clinical trial
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 16 (2) , 92-97
Abstract
Intravenous immunoglobulin (IVIG) is the first‐line therapy for multifocal motor neuropathy (MMN). This open‐label multi‐centre study (NCT00701662) assessed the efficacy, safety, and convenience of subcutaneous immunoglobulin (SCIG) in patients with MMN over 6 months, as an alternative to IVIG. Eight MMN patients (42–66 years), on stable IVIG dosing, received weekly SCIG at doses equivalent to previous IVIG using a “smooth transition protocol”. Primary efficacy endpoint was the change from baseline to week 24 in muscle strength. Disability, motor function, and health‐related quality of life (HRQL) endpoints were also assessed. One patient deteriorated despite dose increase and was withdrawn. Muscle strength, disability, motor function, and health status were unchanged in all seven study completers who rated home treatment as extremely good. Four experienced 18 adverse events, of which only two were moderate. This study suggests that MMN patients with stable clinical course on regular IVIG can be switched to SCIG at the same monthly dose without deterioration and with a sustained overall improvement in HRQL.Keywords
This publication has 14 references indexed in Scilit:
- Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case reportNeurological Sciences, 2010
- Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain‐Barré syndromeAnnals of Neurology, 2009
- Subcutaneous immunoglobulin: opportunities and outlookClinical and Experimental Immunology, 2009
- Subcutaneous immunoglobulin therapy for multifocal motor neuropathyJournal of the Peripheral Nervous System, 2009
- Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single‐blinded cross‐over trialEuropean Journal of Neurology, 2009
- European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve SocietyJournal of the Peripheral Nervous System, 2006
- Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insuranceThe European Journal of Health Economics, 2005
- Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at homeJournal of Allergy and Clinical Immunology, 2004
- Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double-blind, placebo-controlled studyBrain, 2001
- The Comparison of the Efficacy and Safety of Intravenous Versus Subcutaneous Immunoglobulin Replacement TherapyJournal of Clinical Immunology, 2000